The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Present at the Rodman & Renshaw Annual Healthcare Conference

Wednesday, September 08, 2010

ARIAD to Present at the Rodman & Renshaw Annual Healthcare Conference07:37 EDT Wednesday, September 08, 2010 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is scheduled to present at the Rodman & Renshaw Annual Healthcare Conference being held at the New York Palace Hotel in New York City, New York. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Tuesday, September 14, 2010 at 9:10 a.m. (ET). The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://investor.ariad.com. A replay of the presentation will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for three weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIAD's other internally discovered product candidates include AP24534, an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia, and AP26113, an investigational anaplastic lymphoma kinase inhibitor, currently in IND-enabling studies. For additional information about the Company, please visit http://www.ariad.com.